Mitochondrial dysfunction has been implicated in the development of heart failure. Oxidative
metabolism in mitochondria is the main energy source of the heart, and the inability to …

The heart consumes large amounts of energy in the form of ATP that is continuously
replenished by oxidative phosphorylation in mitochondria and, to a lesser extent, by …

In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Ischemia/reperfusion injury (IRI) permeates a variety of diseases and is a ubiquitous
concern in every transplantation proceeding, from whole organs to modest grafts. Given its …

A large body of evidence indicates that mitochondrial dysfunction has a major role in the
pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary …

Peripartum cardiomyopathy (PPCM) is a rare, often dilated, cardiomyopathy with systolic
dysfunction that presents in late pregnancy or, more commonly, the early postpartum period …

Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological
mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and …

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used
for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert …